China SXT Pharmaceuticals-ASXTC
13F holders, Q4 2024 (December 31)3holders −4
0new positions
3sold out
$0.49avg. 13F price*
At the end of Q4 2024, 3 institutions reported holding China SXT Pharmaceuticals-A (SXTC) in their 13F filings, down 4 from Q3 2024. 0 opened new positions and 3 sold out. The largest holders were Bank of Montreal ($5K), UBS Group AG ($4) and Acadian Asset Management LLC ($0).
- Company
- China SXT Pharmaceuticals-A
- CUSIP
- G2161P140
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $17K |
All 13F filers, Q3 2024 → Q4 2024: 36,507 shares sold, net −36,507 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Bank of Montreal | 0.00% | No change | 10,000 | $5K |
| UBS Group AG | 0.00% | Reduce -99.9% | 8 | $4 |
| Acadian Asset Management LLC | 0.00% | No change | 379 | $0 |
"% of holder's portfolio" is SXTC's weight in each manager's 13F, not the share of China SXT Pharmaceuticals-A the manager owns.